Literature DB >> 9482249

Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator.

R Katzman1, D Kang, R Thomas.   

Abstract

The Apolipoprotein E4 allele (Apo-epsilon4) is the major susceptibility gene for late onset Alzheimer Disease (AD) but epidemiological data suggest that the effect of this allele is modified in different individuals by genetic or environmental factors. Age and head injury are major non-genetic factors modifying the Apo-epsilon4 risk. There is conflicting data as to whether alleles of other chaperon proteins (such as alpha-1-antichymotrypsin (ACT)) or Apo-epsilon4 receptors (such as the VDRL receptor) modify the Apo-epsilon4 risk for AD. We analyze problems posed by genetic association studies including those of multiple comparisons and selection of controls, the latter problem exacerbated by the wide variations in Apolipoprotein E allele frequencies observed in different groups and localities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482249     DOI: 10.1023/a:1022461601609

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  76 in total

1.  THE PREPARATION AND SOME PROPERTIES OF PURIFIED MYELIN FROM THE CENTRAL NERVOUS SYSTEM.

Authors:  L A AUTILIO; W T NORTON; R D TERRY
Journal:  J Neurochem       Date:  1964-01       Impact factor: 5.372

2.  Presenilin-1 polymorphism and Alzheimer's disease.

Authors:  M J Owen; P Kehoe; J Williams
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

3.  The ultrastructure of purified preparations of neurons and glial cells.

Authors:  C S Raine; S E Poduslo; W T Norton
Journal:  Brain Res       Date:  1971-03-19       Impact factor: 3.252

Review 4.  Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology.

Authors:  B T Hyman; T Gomez-Isla; H West; M Briggs; H Chung; J H Growdon; G W Rebeck
Journal:  Ann N Y Acad Sci       Date:  1996-01-17       Impact factor: 5.691

5.  A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease.

Authors:  A Ueki; M Kawano; Y Namba; M Kawakami; K Ikeda
Journal:  Neurosci Lett       Date:  1993-12-12       Impact factor: 3.046

6.  Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples.

Authors:  D Tsuang; W Kukull; L Sheppard; R L Barnhart; E Peskind; S D Edland; G Schellenberg; M Raskind; E B Larson
Journal:  J Am Geriatr Soc       Date:  1996-06       Impact factor: 5.562

7.  Underexpression of the apolipoprotein E4 isoform in an Italian population.

Authors:  R W James; M Boemi; R Giansanti; P Fumelli; D Pometta
Journal:  Arterioscler Thromb       Date:  1993-10

Review 8.  Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus.

Authors:  M A Cariolou; A Kokkofitou; P Manoli; S Christou; A Karagrigoriou; L Middleton
Journal:  Genet Epidemiol       Date:  1995       Impact factor: 2.135

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  No genetic effect of alpha1-antichymotrypsin in Alzheimer disease.

Authors:  J L Haines; M L Pritchard; A M Saunders; J M Schildkraut; J H Growdon; P C Gaskell; L A Farrer; S A Auerbach; J F Gusella; P A Locke; B L Rosi; L Yamaoka; G W Small; P M Conneally; A D Roses; M A Pericak-Vance
Journal:  Genomics       Date:  1996-04-01       Impact factor: 5.736

View more
  1 in total

Review 1.  Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine.

Authors:  S W Seto; G Y Yang; H Kiat; A Bensoussan; Y W Kwan; D Chang
Journal:  Int J Endocrinol       Date:  2015-04-28       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.